NEVVI Medicare utilization intelligence
CMS RBCS · Durable medical equipment · Drugs Administered Through DME

Drugs Administered Through DME — codes without an RBCS family

7 CPT®/HCPCS codes, ranked by est. all-Medicare services — scaled from national Medicare Part B fee-for-service volume. Open any code for the full market view — ranked physician groups, geography, and 12-year trend.

CMS's RBCS classification leaves these codes at the subcategory level — no family is assigned. We list them; we don't invent a family.

CY2024 · National scale is an all-Medicare estimate · est. — scaled estimate — assumes MA utilization mirrors FFS; not an observation; the observed fee-for-service figure is shown adjacent. Part B · national figures

HCPCS · Drugs Administered Through DME J7999 Compounded drug, not otherwise classified CMS descriptor · HCPCS
Medicare Part B claims
First observed 2016 — first year this code appears in Part B claims
National scale 548,898 services · est. ▼ 16.7% YoY · 74,327 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 267,640 observed fee-for-service services
See the national market for J7999 → ranked groups · states · 12-yr trend
HCPCS · Drugs Administered Through DME J7312 Injection, dexamethasone, intravitreal implant, 0.1 mg CMS descriptor · HCPCS
Medicare Part B claims
First observed 2013 — start of our 12-year window; the code predates it
National scale 242,137 services · est. ▼ 11.1% YoY · 7,967 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 122,136 observed fee-for-service services
See the national market for J7312 → ranked groups · states · 12-yr trend
HCPCS · Drugs Administered Through DME J7308 Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) CMS descriptor · HCPCS
Medicare Part B claims
First observed 2013 — start of our 12-year window; the code predates it
National scale 162,815 services · est. ▲ 7.0% YoY · 53,364 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 81,810 observed fee-for-service services
See the national market for J7308 → ranked groups · states · 12-yr trend
HCPCS · Drugs Administered Through DME J2545 Pentamidine isethionate, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per 300 mg CMS descriptor · HCPCS
Medicare Part B claims
First observed 2013 — start of our 12-year window; the code predates it
National scale 2,254 services · est. ▲ 4.2% YoY · 739 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 1,031 observed fee-for-service services
See the national market for J2545 → ranked groups · states · 12-yr trend
HCPCS · Drugs Administered Through DME J7626 Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mg CMS descriptor · HCPCS
Medicare Part B claims
First observed 2013 — start of our 12-year window; the code predates it
National scale 1,539 services · est. · 594 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 742 observed fee-for-service services
See the national market for J7626 → ranked groups · states · 12-yr trend
HCPCS · Drugs Administered Through DME J7799 Noc drugs, other than inhalation drugs, administered through dme CMS descriptor · HCPCS
Medicare Part B claims
First observed 2013 — start of our 12-year window; the code predates it
National scale 301 services · est. ▼ 53.9% YoY · 58 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 150 observed fee-for-service services
See the national market for J7799 → ranked groups · states · 12-yr trend
HCPCS · Drugs Administered Through DME J7608 Acetylcysteine, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per gram CMS descriptor · HCPCS
Medicare Part B claims
First observed 2013 — start of our 12-year window; the code predates it
National scale 54 services · est. ▼ 24.4% YoY · 12 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 27 observed fee-for-service services
See the national market for J7608 → ranked groups · states · 12-yr trend